title: Chelation therapy in the JCR:LA-cp rat: experimental assessment of a putative antiatherosclerotic treatment.
abstract: OBJECTIVE
  To test the efficacy of chelation therapy, an alternative medical treatment, as an antiatherosclerotic procedure, using an animal model of insulin resistance and vascular disease.
  
  
  METHODS
  A prospective animal experiment with procedures modelled on human chelation treatments.
  
  
  METHODS
  The JCR:LA-cp rat, a strain that, if homozygous for the autosomal recessive cp gene, becomes obese and insulin resistant, with marked hyperinsulinemia and hypertriglyceridemia, and is unique in the spontaneous development of atherosclerosis and ischemic myocardial lesions.
  
  
  METHODS
  Eight-month-old, obese, male JCR:LA-cp rats were fitted with indwelling venous cannulae and infused over 4 weeks with ethylenediaminetetraacetic acid (EDTA) 5 days a week at a daily dose of 40 mg/kg body weight. At the end of the treatment period, samples were taken for assay of blood parameters and for mineral content of bone. The rats were sacrificed and perfusion-fixed for scanning electron microscopy of the aortic arch.
  
  
  RESULTS
  Plasma cholesterol concentrations were not changed by the EDTA treatment. In contrast, plasma triglyceride concentrations were raised significantly (74%, p < 0.05). Lean control rats showed minimal abnormality of the aortic arch, whereas the obese control rats had raised intimal lesions, frequent adherent macrophages and endothelial damage. The frequency of these vascular abnormalities in the EDTA-treated rats was not different from that seen in the obese controls. The bone contents of calcium and magnesium were not significantly reduced.
  
  
  CONCLUSIONS
  Chelation therapy using intravenous EDTA has no beneficial effects on the arterial lesions in the atherosclerotic JCR:LA-cp rat. The increase in plasma triglyceride concentrations would be grounds for concern in human patients.
authors.affiliation: Department of Surgery, University of Alberta, Edmonton.
authors.forename: S F
authors.initials: SF
authors.lastname: O'Brien
authors.forename: S E
authors.initials: SE
authors.lastname: Kelly
authors.forename: P J
authors.initials: PJ
authors.lastname: Dolphin
authors.forename: J C
authors.initials: JC
authors.lastname: Russell
mesh_terms: D000818:Animals; D001013:Aorta, Thoracic / Q000473:pathology; D001161:Arteriosclerosis / Q000188:drug therapy*; D001842:Bone and Bones / Q000737:chemistry; D002118:Calcium / Q000032:analysis; D015913:Chelation Therapy; D000529:Complementary Therapies; D004195:Disease Models, Animal; D004492:Edetic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D004730:Endothelium, Vascular / Q000473:pathology; D007333:Insulin Resistance / Q000235:genetics; D008055:Lipids / Q000097:blood; D008264:Macrophages / Q000473:pathology; D008274:Magnesium / Q000032:analysis; D008297:Male; D008855:Microscopy, Electron, Scanning; D009765:Obesity / Q000235:genetics; D011446:Prospective Studies; D051381:Rats; D011922:Rats, Mutant Strains; D014280:Triglycerides / Q000097:blood
chemical_list: D008055:Lipids; D014280:Triglycerides; D004492:Edetic Acid; D008274:Magnesium; D002118:Calcium